Blog

Innovasis faced a federal healthcare fraud case over claims that the medical device company gave improper financial benefits to spine surgeons. Federal officials alleged that these benefits encouraged doctors to use Innovasis spinal implants and other products in procedures paid for by Medicare. The case did not focus on claims that the implants were defective. Instead, it centered on the financial relationships between the company and physicians and whether those arrangements affected medical device choices.

A major resolution came on May 29, 2024. Innovasis Inc. and senior executives Brent Felix and Garth Felix agreed to pay a total of $12 million to settle allegations under the False Claims Act. Federal officials said the alleged conduct also involved the Anti-Kickback Statute. The settlement ended the federal claims without a court finding that Innovasis or its executives were liable. This guide explains the Innovasis lawsuit, the allegations, the settlement, the whistleblower’s role, and the compliance issues that remain important after the case.

Who Is Innovasis?

Innovasis is a privately held medical device company based in Salt Lake City, Utah. The company says it has worked in the research, development, manufacture, and sale of spinal implant devices and related products since 2004. Its product lines serve several areas of spine surgery and include implants and surgical instruments for cervical, thoracolumbar, and other spinal procedures.

Spinal implants can play an important role in procedures that address conditions such as spinal degeneration, trauma, deformity, and other serious spine problems. Innovasis also provides product resources and education for surgeons. Its current website continues to list spinal implant systems and patient resources, which shows that the company remains active after the federal settlement.

Innovasis Lawsuit at a Glance

The federal case involved alleged payments to doctors rather than claims about a defective medical device. Key facts from the Justice Department provide a clear view of the dispute.

The Justice Department stated that the settlement resolved allegations only. No determination of liability was made against Innovasis, Brent Felix, or Garth Felix.

Innovasis Lawsuit Timeline

The Innovasis case developed over several years before the federal settlement in 2024. This timeline shows the main events and dates connected to the lawsuit.

The settlement resolved the federal civil claims without a determination of liability. HHS-OIG scrutiny is a separate compliance matter that continued after the financial settlement.

What Did the Government Allege Against Innovasis?

Federal officials alleged that Innovasis provided improper benefits to 17 orthopedic surgeons and neurosurgeons from January 1, 2014 through December 31, 2022. According to the Justice Department, the purpose of those benefits was to encourage the doctors to use Innovasis spinal implants, devices, and other equipment during procedures performed on Medicare patients.

Brent Felix founded Innovasis and served as its president and chairman at the time described by the Justice Department. Garth Felix held several senior roles at the company, including chief financial officer. Federal officials alleged that the two brothers controlled or directed company operations, major business decisions, and agreements with surgeons who received the alleged benefits.

These claims did not mean that the defendants had already violated the law. They remained government allegations. The $12 million settlement resolved the civil claims without a final finding of liability.

What Types of Payments Were Part of the Allegations?

The case covered several types of alleged financial benefits. Federal officials did not limit their claims to direct cash payments. They also examined business agreements, travel, events, and other forms of compensation.

According to the Justice Department, the alleged benefits included:

• Consulting fees, including payments that the government said exceeded fair market value in certain cases
• Intellectual property purchase and licensing payments
• Payments connected to a medical data registry
• Performance shares in Innovasis
• Travel and lodging at a luxury ski resort
• Expensive dinners and holiday events for surgeons, staff members, and family members

Federal officials also alleged that certain doctors received consulting payments for work that was never performed. Other claims involved intellectual property that Innovasis allegedly bought or licensed without a prior valuation and later did not use for meaningful product development. The government also cited a company conference at a luxury resort in Deer Valley, Utah.

How the Anti-Kickback Statute Applies to the Case

The federal Anti-Kickback Statute restricts payments or other items of value that are offered to encourage referrals or use of healthcare items and services paid for through federal healthcare programs. The rule seeks to protect medical decisions from improper financial influence.

A normal business relationship between a doctor and a medical device company is not automatically illegal. Medical companies may have legitimate reasons to pay physicians for real work, research, education, or product advice. Legal risk can arise when payment serves as a reward or incentive for the physician to use a specific product in federally funded care.

In the Innovasis case, federal officials alleged that certain benefits were tied to surgeons’ use of the company’s devices in procedures for Medicare beneficiaries. That alleged connection formed a key part of the government’s case.

Role of the False Claims Act

The False Claims Act gives the federal government a way to pursue fraud that affects public funds. Healthcare cases may involve this law when an alleged kickback leads to claims for payment from Medicare or another federal healthcare program.

The Innovasis settlement used this legal framework. Federal officials alleged that improper payments influenced product use in Medicare procedures. That link allowed the government to pursue civil False Claims Act claims tied to the alleged Anti-Kickback Statute violations.

False Claims Act cases can also begin through a private whistleblower action. A person with relevant information may file a case on behalf of the United States under provisions often called qui tam rules. A successful whistleblower may receive part of the government’s recovery.

Who Was the Innovasis Whistleblower?

Robert Richardson, a former Innovasis Regional Sales Director, brought the whistleblower claims involved in the settlement. The case was filed as United States ex rel. Richardson v. Innovasis Inc., et al., No. 3:19-CV-02440-X, in the U.S. District Court for the Northern District of Texas.

Richardson used the False Claims Act’s qui tam provisions to bring claims on behalf of the United States. After the $12 million resolution, the Justice Department stated that he would receive approximately $2.2 million as his share of the federal recovery. Richardson’s role also illustrates how the False Claims Act allows a private person with relevant information to bring claims on behalf of the United States.

Innovasis $12 Million Settlement Explained

Innovasis, Brent Felix, and Garth Felix agreed to a total payment of $12 million to resolve the federal allegations. The Justice Department announced the settlement on May 29, 2024. It covered claims tied to the alleged improper physician payments and their connection to the use of Innovasis devices in Medicare procedures.

A civil settlement does not have the same meaning as a court judgment after a trial. The parties can resolve a dispute without a judge or jury deciding that the allegations are true. That distinction matters in this case. The Justice Department specifically stated that the claims resolved through the agreement were allegations and that there had been no determination of liability.

This means it would be inaccurate to say that Innovasis was found guilty in this matter. It would also be inaccurate to describe the lawsuit as still awaiting a verdict. The federal claims covered by the agreement reached a settlement in 2024.

HHS-OIG Scrutiny After the Settlement

After the settlement, HHS-OIG continued to list Innovasis under Heightened Scrutiny. Key points include:

• HHS-OIG says Innovasis did not agree to compliance oversight through a Corporate Integrity Agreement (CIA).
• The agency reserved the right to exclude Innovasis from federal healthcare programs based on the alleged conduct.
• HHS-OIG may use other tools to monitor the company’s compliance.
• Innovasis has not been automatically excluded from federal healthcare programs.
• The $12 million settlement and HHS-OIG compliance oversight are separate matters.

Was the Innovasis Lawsuit About Defective Spinal Implants?

The Justice Department’s settlement announcement did not describe the Innovasis case as a defective medical device lawsuit. It also did not state that Innovasis implants caused patient injuries. The federal claims focused on alleged financial arrangements with doctors and the use of Innovasis products in Medicare-funded procedures.

That difference is important for patients who may see the word “lawsuit” and assume that the case involved unsafe implants. Product safety claims and kickback claims are separate legal issues. The 2024 federal settlement addressed alleged payments and healthcare fraud. It did not establish that a specific Innovasis implant was defective or that a patient suffered harm from one.

Patients with questions about a device used in their own surgery should check their medical records and speak with a qualified healthcare professional. A federal payment settlement alone cannot show whether an individual medical device caused a health problem.

What the Innovasis Case Means for Healthcare Compliance

Medical device companies can work with surgeons on research, product advice, and education, but payments should reflect real work and fair value. Problems can arise if money, travel, shares, or other benefits influence which products doctors use.

The Innovasis case shows why federal agencies review consulting deals, intellectual property payments, travel, events, and other financial ties. Clear contracts, fair compensation, proper records, and independent medical decisions can help reduce legal and compliance risk.

Is Innovasis Still in Business?

Innovasis continues to operate and maintains an active website with spinal device products, patient resources, and company information. The 2024 settlement resolved specific federal civil allegations and did not represent a company closure. HHS-OIG’s heightened scrutiny status is a separate compliance matter tied to federal healthcare oversight.

Conclusion

Innovasis reached a major legal resolution on May 29, 2024, when the company and senior executives Brent Felix and Garth Felix agreed to pay $12 million to resolve federal allegations. Officials alleged that improper financial benefits were provided to 17 spine surgeons from 2014 through 2022 to encourage use of Innovasis products in Medicare procedures. Former Innovasis Regional Sales Director Robert Richardson brought the whistleblower claims and was set to receive about $2.2 million from the federal recovery.

No court finding established liability against Innovasis or its executives, and the case was not presented as a defective implant or patient injury lawsuit. HHS-OIG continues to list Innovasis under heightened scrutiny after the company did not agree to a Corporate Integrity Agreement. This makes the case mainly a healthcare compliance and False Claims Act matter rather than a product safety dispute.

Common Questions